Correlation Of Dre, Psa, Trus And Trus Guided Biopsy In Prostate Cancer – Our Institutional Study

Background: The aim of the study is to correlate between the value of digital rectal examination (DRE), serum prostate-specific antigen (PSA), and transrectal ultrasound (TRUS) guided biopsy as predictors for diagnosing prostate cancer and to find out whether combined modality is better in screening and detection of prostate cancer. Materials and Methods: A total of 62 male patients seen over a period of 2 years in a single institution with abnormal DRE, serum PSA levels, TRUS and TRUS guided biopsy and correlated. Results: TRUS biopsy revealed prostate cancer in 26 out of 62 patients. 60% of patients with abnormal DRE had cancer prostate and the remainder 40% reported to have benign lesions. And 92% of patients with abnormal PSA levels had cancer prostate on trus biopsy. Combined abnormal PSA and DRE revealed cancer in 88% of patients. This percentage increased to 95% when TRUS was also abnormal, but dropped to 77% when TRUS was normal. Conclusion: Digital rectal examination together with serum PSA and TRUS have the highest predictable values for diagnosis of prostate cancer. Serum PSA alone is more predictable than DRE in our study. TRUS guided biopsies should be performed in the presence of high serum PSA, and/or abnormal findings by DRE.